Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Badger Meter Inc (BMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Badger Meter Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $299.75 (market cap $8.04B), while Badger Meter Inc trades at $142.49 (market cap $4.13B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is the larger of the two by market cap, and Badger Meter Inc pays a 1.13% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | BMI | |
|---|---|---|
Market Cap | $8.04B | $4.13B |
Sector | Health | Technology |
52-Week High | $339.75 | $245.81 |
52-Week Low | $241.71 | $113.41 |
Enterprise Value | $7.85B | $3.92B |
Dividend Yield | — | 1.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Badger Meter (BMI) trades at $140.12, down 2.82% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. Fundamentally, the company reported $917M revenue and $142M net income for 2025, with strong profitability margins but recent earnings misses in Q4 2025 and Q1 2026. A securities class action lawsuit filed in July 2026 adds significant near-term uncertainty, though analyst consensus remains a Buy with a $144.60 price target.
The stock faces headwinds from legal risks and earnings volatility, but solid fundamentals and analyst support suggest potential recovery if legal concerns subside. Investors should weigh the high valuation multiples against operational strength and monitor lawsuit developments closely for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Badger Meter Inc
Badger Meter provides industry-leading water management solutions. Its smart measurement hardware and software analytics help water utilities and industrial customers optimize operations and conserve natural resources.
Read more on BMI →
